The U.S. Food and Drug Administration has approved Pfizer’s HIV entry inhibitor Selzentry (maraviroc), which is expected to be available by mid-September. The drug, which attacks CCR5 receptors on CD4 cells, is the premiere member of the first new class of oral HIV medications in over a decade.